Developmental Research Program

胰腺癌孢子的发展研究计划（DRP）的使命是确定 并资助发展研究项目，这些项目探索具有显著潜力的创新想法， 胰腺癌的发病率、发病率和死亡率。此外，我们建议让莫尔豪斯 医学院（MSM）和塔斯基吉大学（TU）在这两个程序和职业发展 整个SPORE计划。胰腺孢子和UAB综合癌症中心 (CCC)在获得和管理发展研究基金方面有成功的记录。还 预防医学司，该司设有CCC生物统计和信息学股以及少数民族中心。 健康和研究中心，有几年的生产合作与男男性接触者和TU有关， 这些节目。 DRP是UAB胰腺、乳腺、脑和既往卵巢检查中最有价值和最具生产力的组成部分。 SPORE程序。胰腺癌创新研究思路的发展 提供灵活的资金。这个胰腺癌孢子打算资助6个发展试点 项目每年（两个在UAB和四个在UMN，包括那些从男同性恋者和TU选择）。这些项目将 每年供资5万美元（6个项目每年需要30万美元）。这些资金来自拟议的 SPORE预算（50，000美元UAB预算和50，000美元UMN预算），UAB机构资金（50，000美元）和UMN 机构资金（150 000美元），如机构承诺书所述。资助期限为1年， 可根据进展情况再延长一年。 DRP的成功取决于其招募和培训初级或新的胰腺癌研究者的能力。 致力于转化型胰腺癌研究的癌症患者。成功的基准 计划包括获奖者参与重大项目，发表转化性胰腺癌 在优秀的同行评审期刊上进行研究，并获得外部同行评审资金。这一重大成功 DRP一直是UAB和UMN科学家的参与，以前没有专门关注胰腺 癌特别是，克里斯·克鲁格博士是一位非常优秀的分子生物学家，他的主要重点是 急性白血病和白血病鼠模型。他的项目将他的分子遗传学专业知识 转基因胰腺癌模型，这已进展到一个重大项目，这一竞争性的更新 重新提交同样，外科副教授Dan Saltzman博士对以下方面也有浓厚的兴趣： 通过减毒Sa/mone/a-IL-2增强免疫系统以对抗儿童肝母细胞瘤。 他与Chris Klug博士（项目1）的合作导致了一种新的同源基因的开发， 免疫活性胰腺癌小鼠模型，Salmonetla-1 L-2的成功IND和FDA批准 免疫毒素用于胰腺癌临床试验，最近资助（2008）R21。另一个DRP成功， 最突出的是Martin约翰逊博士，他以前的工作集中在结肠FU的药物基因组学上 癌约翰逊博士开发了一种通过MA-RT-PCR的关键测定法，以评估纳克量的RNA， 胰腺FNA样品。约翰逊博士的工作产生了两个出版物，记录了再现性 以及技术和样品采集的准确性。这已被证明是组织的关键要素 为项目3的相关研究提供了进一步的依据.这项计划的成功 我们正在少数民族机构进行两项试点研究，

The mission of the Developmental Research Program (DRP) of the Pancreatic Cancer SPORE is to identify and fund developmental research projects which explore innovative ideas with significant potential to reduce the incidence, morbidity, and mortality of pancreatic cancer. Further, we propose to involve both Morehouse School of Medicine (MSM) and Tuskegee University (TU) in both this program and the Career Development Program of the overall SPORE. Both the Pancreatic SPORE and the UAB Comprehensive Cancer Center (CCC) have successful track records for obtaining and administering developmental research funds. Also, the Division of Preventive Medicine, which houses both the CCC Biostatistics and Informatics Unit and the Minority Health and Research Center, has several years of productive collaboration with both MSM and TU relevant to these programs. The DRP is a most valuable and productive component ofthe UAB Pancreas, Breast, Brain, and prior Ovarian SPORE programs. The development of innovative research ideas in pancreatic cancer is critically dependent on the availability of flexible funding. This Pancreatic Cancer SPORE intends to fund 6 developmental pilot projects annually (two at UAB and four at UMN, including those selected from MSM and TU). The projects will be funded at $50,000/year (6 projects will require $300,000/year). The funds are derived from the proposed SPORE budgets ($50,000 UAB budget and $50,000 UMN budget), UAB institutional funds ($50,000) and UMN institutional funds ($150,000) as described in the institutional letters of commitment. Funding is for 1 year and is renewable for 1 additional year depending on progress. The success of a DRP is determined by its ability to recruit and train junior or new investigators in pancreatic cancer who are committed to translational pancreatic cancer research. The benchmarks for success of the program include participation of awardees in major projects, publication of translational pancreatic cancer research in excellent peer-reviewed journals, and external peer-reviewed funding. A major success of this DRP has been the engagement of UAB and UMN scientists previously not focused specifically on pancreatic cancer. In particular, Dr. Chris Klug is a very good molecular biologist whose major emphasis had been in acute leukemia and leukemic murine models. His project brought his molecular genetic expertise into transgenic pancreatic cancer models, which has progressed to a major Project of this competitive renewal resubmission. Similarly, Dr. Dan Saltzman, Associate Professor of Surgery, has a committed interest in augmentation of the immune system through attenuated Sa/mone//a-lL-2 to fight hepatoblastoma in children. His collaboration with Dr. Chris Klug (Project 1) led to the development of a novel syngeneic immunocompetent pancreatic cancer mouse model, successful IND, and FDA approval ofthe Salmonetla-\L-2 immunotoxin for pancreatic cancer clinical trial with a recently funded (2008) R21. Another DRP success to highlight is Dr. Martin Johnson, whose prior efforts were focused on the pharmacogenomics of FU in colon cancer. Dr. Johnson developed a critical assay via MA-RT-PCR to evaluate nanogram quantities of RNA from pancreatic FNA samples. Dr. Johnson's work has produced two publications documenting the reproducibility and accuracy of the technique and sample acquisition. This has proven to be a critical element of the Tissue Core and has provided further basis for correlative studies proposed in Project 3. The success of this program is also evidenced in that we have 2 pilot studies ongoing at minority institutions